"Furthermore, we developed RC-1, a reversible covalent BTK PROTAC that was effective as both a BTK inhibitor and degrader," said co-first author Dr. Xiaoli Qi, assistant professor in pharmacology ...

Making an improved PROTAC . The researchers worked with a well-known target of PROTAC, the enzyme Bruton’s tyrosine kinase (BTK). They used different types of binders – reversible noncovalent, ...

Gluetacs Therapeutics (Shanghai) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moiety covalently linked to a Bruton tyrosine kinase ...